Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Aliskiren and losartan trial in non-diabetic chronic kidney disease.

Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Fook-Chong S, Lee EJ, Anantharaman V, Lee GS, Chan CM.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):515-22. doi: 10.1177/1470320313510584. Epub 2014 Apr 17.

PMID:
24742970
2.

Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.

Wu MT, Tung SC, Hsu KT, Lee CT.

J Renin Angiotensin Aldosterone Syst. 2014 Sep;15(3):271-7. doi: 10.1177/1470320312467560. Epub 2012 Dec 7.

PMID:
23223162
3.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

4.

AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.

Fraune C, Lange S, Krebs C, Hölzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1037-48. doi: 10.1152/ajprenal.00672.2011. Epub 2012 Jul 11.

5.

A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease.

Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Stephanie FC, Lee EJ, Anantharaman V, Lee GS, Chan CM.

World J Nephrol. 2013 Nov 6;2(4):129-35. doi: 10.5527/wjn.v2.i4.129.

6.

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH; AVOID Study Investigators.

Diabetes Care. 2010 Nov;33(11):2304-9. doi: 10.2337/dc10-0833. Epub 2010 Aug 6.

7.

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.

Hypertens Res. 2012 Aug;35(8):874-81. doi: 10.1038/hr.2012.45. Epub 2012 May 17.

PMID:
22592665
8.

Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.

Abe M, Suzuki H, Okada K, Maruyama N, Inoshita A, Baba S, Takashima H, Soma M.

Heart Vessels. 2013 Jul;28(4):442-52. doi: 10.1007/s00380-012-0260-7. Epub 2012 May 23.

PMID:
22618635
9.

Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.

Guo LL, Pan Y, Jin HM.

Nephrol Dial Transplant. 2009 Jun;24(6):1876-83. doi: 10.1093/ndt/gfn770. Epub 2009 Jan 22.

PMID:
19164322
10.

Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.

Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.

Int Urol Nephrol. 2012 Dec;44(6):1763-70.

11.

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.

Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K.

Int Urol Nephrol. 2012 Jun;44(3):841-5. doi: 10.1007/s11255-011-9991-0. Epub 2011 May 28.

PMID:
21626132
12.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators.

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

13.

Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.

Imbalzano E, Scarpelli M, Mandraffino G, Creazzo M, Lizio G, Trapani G, Dattilo G, Dalbeni A, Tomasello C, Sardo MA, Saitta A.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):956-64. doi: 10.1177/1470320314530018. Epub 2014 Jul 27.

PMID:
25070350
14.

Aliskiren and dual therapy in type 2 diabetes mellitus.

Ingelfinger JR.

N Engl J Med. 2008 Jun 5;358(23):2503-5. doi: 10.1056/NEJMe0803375. No abstract available.

PMID:
18525047
15.

Are we ready to use aliskiren in children?

Kelland EE, McAuley LM, Filler G.

Pediatr Nephrol. 2011 Mar;26(3):473-7. doi: 10.1007/s00467-010-1702-z. Epub 2010 Dec 11.

PMID:
21153557
16.

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.

Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S.

J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):122-7. doi: 10.1177/1470320311422580. Epub 2011 Sep 23.

PMID:
21946392
17.

Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease.

Shen PC, He LQ, Yang XJ, Cao HX.

J Investig Med. 2012 Oct;60(7):1041-7. doi: 10.2310/JIM.0b013e31826741d2.

PMID:
22914601
18.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

PMID:
19145003
19.

The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK.

PLoS One. 2013 May 10;8(5):e62736. doi: 10.1371/journal.pone.0062736. Print 2013.

20.

The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.

Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.

Kidney Blood Press Res. 2012;36(1):335-43. doi: 10.1159/000343391. Epub 2012 Dec 12.

Supplemental Content

Support Center